Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism: A case report.

Abstract

RATIONALE:

Rivaroxaban has numerous advantages over traditional anticoagulation therapy. Fixed doses can be administered without requiring routine monitoring of coagulation, and anticoagulation efficacy is more predictable. Safety, including fewer drug interactions, and reduced bleeding, is also improved with rivaroxaban based on current recommendations. The goal of this report was to explore if low-dose rivaroxaban 10 mg once daily was effective in an elderly patient who developed minor bleeding when treated with rivaroxaban (10 mg twice daily) for a pulmonary embolism.

PATIENT CONCERNS:

We present an 88-year-old female with dyspnea and fatigue, which became increasingly worse over a month in the absence of medication. Her weight was 64 kg. Routine coagulation assays and renal function were normal at time of admission.

DIAGNOSIS:

Deep vein thrombosis and pulmonary embolism were confirmed by venous compression ultrasonography and computed tomography pulmonary angiography.

INTERVENTIONS:

Oral rivaroxaban 10 mg twice daily was administered, but the patient developed hemoptysis and gum bleeding 5 days later. The dose of rivaroxaban was reduced to 10 mg once daily, and bleeding gradually disappeared after 3 days.

OUTCOME:

At follow-up 90 days after treatment, the patient reported no discomfort. Venous compression ultrasonography and computed tomography pulmonary angiography showed normal results; therefore, treatment was terminated.

LESSONS:

Elderly patients exhibit variable tolerance of anticoagulants, warranting careful consideration of the risk of bleeding. Low-dose rivaroxaban was an effective treatment for pulmonary embolism in the elderly patient presented here.

• Authors: Huanyu Zhou, Qi Wei, Haidi Wu, Minglong Tang, Shuo Yang, Yang Liu, Ling Qin
• Journal: Medicine (Medicine (Baltimore)) Vol. 98 Issue 20 Pg. e15705 (May 2019) ISSN: 1536-5964 [Electronic] United States
• PMID: 31096518 (Publication Type: Case Reports, Journal Article)

Chemical References

• Factor Xa Inhibitors
• Rivaroxaban

Topics

• Administration, Oral
• Aftercare
• Aged, 80 and over
• Computed Tomography Angiography (methods)
• Factor Xa Inhibitors (administration & dosage, adverse effects, therapeutic use)
• Female
• Hemorrhage (etiology, prevention & control)
• Humans
• Pulmonary Embolism (diagnostic imaging, drug therapy)
• Rivaroxaban (administration & dosage, adverse effects, therapeutic use)
• Treatment Outcome
• Ultrasonography (methods)
• Venous Thrombosis (diagnostic imaging, drug therapy)